TABLE 2.
Clinical outcomes (n = 136).
| Baseline (n = 136) | 6 months (n = 136) | 18 months (n = 71) | p a | |
|---|---|---|---|---|
| Grade group | ||||
| No Cancer | 0 (0%) | 89 (66%) | 33 (46%) | NA |
| GG1 | 5 (4%) | 14 (10%) | 13 (18%) | |
| GG2 | 88 (65%) | 24 (18%) | 17 (24%) | |
| GG3 | 35 (26%) | 7 (5%) | 5 (7%) | |
| GG4 | 8 (6%) | 2 (1%) | 3 (4%) | |
| GG5 | 0 (0%) | 0 (0%) | 0 (0%) | |
| MCCL, mm, median (IQR) | 7 (5, 9) | 3 (2, 5) | 3 (2, 5) | All <0.01 |
| PSA, ng/mL | ||||
| Median (IQR) | 6.9 (4.9, 9.9) | 2.5 (1.3, 4.3) | 2.5 (1.4, 4.1) | All <0.01 |
| <4 | 13 (10%) | 95 (70%) | 53 (75%) | All <0.01 |
| 4–10 | 89 (65%) | 39 (29%) | 16 (23%) | |
| >10 | 34 (25%) | 2 (1%) | 2 (3%) | |
| Prostate volume, cc, median (IQR) | 42.5 (33.4, 54.8) | 34.9 (26.0, 45.0) | 33 (25, 46) | <0.01, <0.01, 0.44 |
| % Decrease | — | 16.5 (5.6, 26.7) | ‐3.2 (‐16.2, 8.0) | — |
| PSA Density, ng/mL/cc | ||||
| Median (IQR) | 0.15 (0.12, 0.25) | 0.06 (0.04, 0.11) | 0.06 (0.04, 0.11) | <0.01, <0.01, 0.08 |
| ≤0.15 | 66 (49%) | 113 (83%) | 61 (87%) | <0.01, <0.01, 0.76 |
| >0.15 | 69 (51%) | 23 (17%) | 9 (13%) | |
| % PSA decrease from baseline, median (IQR) | — | 65% (40, 80) | 57% (37, 75) | — |
| % Free PSA, mg/mL, median (IQR) | 13 (10, 17) | 16 (12, 22) | 18 (12, 25) | <0.01, <0.01, 0.93 |
a
Kappa test of agreement or Wilcoxon signed rank sum test for ssbaseline vs 6 months, baseline vs 18 months, and 6 months vs 18 months.